The Food and Drug Administration (FDA) is scaling back its authorization of the use of convalescent blood-plasma for COVID-19 patients in an effort to guide physicians who have faced a confusing thicket of data about the therapy’s effectiveness.

The agency said late Thursday that the authorization, a subject of controversy since it was first issued last August, would be revised to limit the use of plasma to hospitalized patients early in the course of the disease and hospitalized patients with a medical condition that impairs their ability to make antibodies.

Patients will be allowed to receive only plasma containing high concentrations of antibodies.

Read More